QELBREE
What it isNorepinephrine-reuptake inhibitor with serotonergic activity; ADHD.
Why this oneIt is a noncontrolled ADHD treatment with serotonergic activity that atomoxetine lacks.
What limits itStrong CYP1A2 inhibition can sharply raise clozapine or theophylline exposure; somnolence and suicidality also matter.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| ADHD | pediatric 6-11y | 100 mg QD | titrate to response | 400 mg QD |
| ADHD | pediatric 12-17y | 200 mg QD | titrate to response | 400 mg QD |
| ADHD | adult | 200 mg QD | titrate to response | 600 mg QD |
Titration Increase at weekly intervals (100 mg peds 6-11y; 200 mg peds 12-17y and adults)
Renal Severe (eGFR <30): start 100 mg QD, titrate weekly by 50-100 mg to max 200 mg QD
Hepatic Undefined
Pregnancy May cause maternal harm; discontinue when pregnancy is recognized unless benefit outweighs risk
Lactation Low transfer into breastmilk (relative infant dose ~1%)
⚠ BOXED WARNING
Cost, est. cash$300–$2,500/month
Generic entry2033 est.
Legacy pregnancy categoryNot assigned — PLLR-era drug
Defining liabilitySomnolence or activation, blood-pressure effects and suicidal-thinking warning in younger patients.

Open Viloxazine in the interactive console ↗

